1
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (19 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2

3
DUDKIN VADIM: Aminobenzotriazole derivatives. MERCK SHARP & DOHME, October 7, 2010: WO/2010/114726 (23 worldwide citation)

The present invention is directed to aminobenzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and di ...


4
ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J, December 15, 2011: WO/2011/156245 (17 worldwide citation)

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseas ...


5
DUDKIN VADIM Y: Ether benzotriazole derivatives. MERCK SHARP & DOHME, February 24, 2011: WO/2011/022312 (13 worldwide citation)

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and d ...


6
Danishefsky Samuel, Dudkin Vadim, Geng Xudong, Mandal Mihiribaran, Olson William, Orlova Marianna: Glycopeptide dimers and uses thereof. Progenics Pharmaceuticals, Sloan Kettering Institute For Cancer Research, Danishefsky Samuel, Dudkin Vadim, Geng Xudong, Mandal Mihiribaran, Olson William, Orlova Marianna, WHITE John P, February 16, 2006: WO/2006/017180 (9 worldwide citation)

This invention provides compounds represented by the formula: (A-X---)n wherein each A- is independently a carbohydrate represented by the general structure: wherein each of B, C, D, E, F, G, H, I, and J independently represents a sugar moiety, a sugar moiety having a protecting group attached there ...


7
Danishefsky Samuel J, Dudkin Vadim, Miller Justin: Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.. Sloan Kettering Institute For Cancer Research, Danishefsky Samuel J, Dudkin Vadim, Miller Justin, LAGNEAU Nadège M, July 22, 2004: WO/2004/060915 (7 worldwide citation)

The present invention provides compounds having formula (I): wherein W1, W2, R1, R3, R4, R2A and R2B are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods of use thereof in the treatment of cancer, methods for the prevention of recurren ...


8
TELLERS David, COLLETTI Steven L, DUDKIN Vadim, IKEMOTO Norihiro, LIAO Hongbiao, PARISH Craig, PEI Tao, SHAW Anthony, TRUONG Quang, WANG Lijun, YUAN Yu, ZHU Man: [fr] NOUVEAUX CONJUGUÉS CONTENANT TÉTRAGALNAC ET PROCÉDÉS POUR LADMINISTRATION DOLIGONUCLÉOTIDES, [en] NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES. MERCK SHARP & DOHME, TELLERS David, COLLETTI Steven L, DUDKIN Vadim, IKEMOTO Norihiro, LIAO Hongbiao, PARISH Craig, PEI Tao, SHAW Anthony, TRUONG Quang, WANG Lijun, YUAN Yu, ZHU Man, November 7, 2013: WO/2013/166121 (7 worldwide citation)

[en] Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizi ...


9
BUNDA Jaime L, COX Christopher D, DUDKIN Vadim Y, FIJI Hannah D, KELLY Michael J III, LAYTON Mark E, PERO Joseph E, SHIPE William D, STEEN Justin T: COMPOSÉS DISOINDOLINONE UTILES COMME INHIBITEURS DE PDE 10, ISOINDOLINONE PDE10 INHIBITORS. MERCK SHARP & DOHME, BUNDA Jaime L, COX Christopher D, DUDKIN Vadim Y, FIJI Hannah D, KELLY Michael J III, LAYTON Mark E, PERO Joseph E, SHIPE William D, STEEN Justin T, May 3, 2012: WO/2012/058133 (6 worldwide citation)

The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychi ...


10
Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Wang Cheng, Hoffman Jacob M, Kreatsoulas Constantine: Inhibitors of checkpoint kinases. Merck & Co, Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Wang Cheng, Hoffman Jacob M, Kreatsoulas Constantine, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, December 21, 2006: WO/2006/135604 (6 worldwide citation)

The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of t ...



Click the thumbnails below to visualize the patent trend.